New Generation Obesity Drugs Dramatically Reduce Alcohol Consumption
Summary
New generation obesity drugs such as Ozempic, Wegovy and Mounjaro are being linked to a sharp drop in alcohol cravings and drinking levels. Researchers say the medicines may affect the brain’s reward response, though doctors caution that larger long-term trials are still needed before they can be used to treat alcohol addiction.
Key Points
- Users of obesity drugs like Ozempic, Wegovy and Mounjaro are reporting reduced alcohol cravings alongside weight loss.
- Studies suggest the drugs may work by mimicking GLP-1 and altering the brain’s reward response.
- Doctors say the possible use of these medicines for alcohol addiction still needs larger, long-term clinical trials.
- Experts warn that the drugs can also cause serious side effects such as pancreatitis.
